Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Market Capitalization on January 14, 2025: USD 25.15 M

Oncopeptides AB (publ) Market Capitalization is USD 25.15 M on January 14, 2025, a -41.79% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Oncopeptides AB (publ) 52-week high Market Capitalization is USD 48.61 M on August 13, 2024, which is 93.29% above the current Market Capitalization.
Oncopeptides AB (publ) 52-week low Market Capitalization is USD 22.14 M on November 11, 2024, which is -11.95% below the current Market Capitalization.
Oncopeptides AB (publ) average Market Capitalization for the last 52 weeks is USD 36.00 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years